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Abstract
Objectives To assess the clinical impact of 18F-fluorodeoxy-
glucose positron emission tomography-computed tomogra-
phy (FDG PET-CT) compared with contrast-enhanced com-
puted tomography (CECT) in patients referred via the Spe-
cialist Skin Cancer Multidisciplinary Team (SSMDT) with
recurrent stage III/IV malignant melanoma (MM).
Methods Forty-five patients were referred for further evalua-
tion with FDG PET-CT. Findings on FDG PET-CT were
compared with prior CECT and the clinical impact on subse-
quent management decisions was determined retrospectively.
A major clinical impact was defined as a change in treatment
plan resulting from identification of additional sites of disease
or by characterisation of indeterminate findings on prior im-
aging. A minor impact was defined as confirmation of known
sites of disease as identified on prior CECT.
Results Fifty-one PET-CT examinations were performed.
FDG PET-CT had a major clinical impact in 21 cases
(41.2 %), of which 18 examinations were performed in pa-
tients with proven or suspected stage IV MM. FDG PET-CT
had a minor impact in 23 cases (45.1 %), and there were five
false-positive cases (9.8 %) and two false-negative cases
(3.9 %).
Conclusion FDG PET-CT is an effective tool in recurrent
stage III/IV MM with a significant clinical impact on man-
agement decisions in patients who are appropriately referred
via the highly specialised forum of the SSMDT.
Key Points
• FDG PET-CT is an effective tool in recurrent stage III/IV
malignant melanoma.
• FDG PET-CT has a significant clinical impact on manage-
ment decisions.
• Effective use of FDGPET-CT is via referral from the Specialist
Skin Cancer Multidisciplinary Team.
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Introduction
Malignant melanoma (MM) is an aggressive form of skin
cancer. The degree of disease dissemination at presentation is
one of the most important predictors of survival in MM. Pa-
tients with loco-regional disease (stage III) have a significant
risk of disease recurrence despite comprehensive surgery [1, 2]
with 5-year survival rates between 40 % and 78 % [3, 4].
Patients with distant metastatic disease (stage IV) have a worse
outlook with a reported median survival of 7–9 months [3],
although this is improving with increasing availability of re-
cently developed and successfully trialled novel chemothera-
peutic agents [5–7].
Surgery is the cornerstone of management in MM and is
offered even in stage IV disease where a complete metastasec-
tomy for oligometastatic disease can confer a survival benefit
greater than that provided by conventional systemic therapy
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[8]. However, the pattern of disease spread in MM is
unpredictable and does not necessarily occur in a sequential
local to regional to distant metastatic pattern [2]. In addition,
recurrent disease occurs in a large proportion of individuals
following resection (approximately 30 %), with the highest
risk in those with late stage disease, where 50–80% of patients
with loco-regional disease and 95 % of those with distant
metastatic disease are likely to relapse [2]. Hence, it is of
fundamental importance that accurate staging is undertaken
in both the primary and recurrent setting, to prognosticate as
well as identify sites of disease that may either alter the
proposed surgical approach or even preclude surgery altogeth-
er and therefore necessitate alternative forms of treatment.
In late stage disease, accurate staging has been achieved
using contrast-enhanced computed tomography (CECT) and
magnetic resonance imaging (MRI), and more recently 18F-
fluorodeoxyglucose positron emission tomography-computed
tomography (FDG PET-CT) [9, 10]. FDG PET-CT has
emerged as an effective tool for staging MM due to a number
of reasons. Melanoma metastases are usually extremely FDG-
avid, owing to their high proliferation rate and hexokinase
activity, resulting in excellent visualisation on FDG PET
imaging [11], and the technique offers total body coverage,
which is ideally suited to MM and its unpredictable pattern of
disease spread [12, 13]. The addition of the CT component
overcomes the inherent limitations of FDG PET in lesion
localisation and characterisation, particularly in the context
of FDG-negative disease, and results in an overall improved
diagnostic accuracy for the detection of distant metastatic
disease when compared with FDG PET imaging alone or
CECT [13–16]. However, accuracy still remains somewhat
limited, specifically in context of sub-centimetre-sized FDG-
negative lung metastases and brain metastases [15–18].
In our institution, referral of patients for evaluation with
FDG PET-CT is made via the highly specialised forum of the
Specialist Skin Cancer Multidisciplinary Team (SSMDT). It
affords all patients with stage IB or higher primary MM and
any patient with metastatic disease, at diagnosis or follow-up,
access to specialist services and clinical expertise [19]. The
multidisciplinary approach is the standard of care for the
delivery of optimal oncological patient management through-
out the UK [20] and has been shown to be associated with
improved survival through benefits gained by specialist re-
view of imaging, improved accuracy of staging and resultant
optimisation of surgical management [21].
Several studies have investigated the clinical impact of
FDG PET-CT in MM but none in the setting of a multidisci-
plinary team experience. The majority have shown that FDG
PET-CT significantly alters management decisions, but a sig-
nificant limitation common to many of these studies is the
marked heterogeneity of patient cohorts [16, 18, 22–26].
The aim of this study was to assess the clinical impact of
FDG PET-CT, compared with CECT of the chest, abdomen
and the pelvis, in a homogeneous cohort of patients with
recurrent stage III/IV melanoma, who have been discussed
and appropriately referred via the SSMDT.
Materials and methods
Inclusion criteria
Formal institutional board review and ethical approval was not
required for this retrospective analysis. Between June 2008
and June 2012, 85 consecutive FDG PET-CT examinations in
patients with MM were performed. Individual electronic case
notes for all patients were reviewed to determine eligibility for
entry into the study and to obtain specific demographic,
clinical and radiological information. Inclusion criteria were
as follows: (1) prior history of treated early stage MM with
suspected or proven stage III/IV recurrence; (2) review and
referral for FDG PET-CT examination by the SSMDT; (3)
staging with CECT of the chest, abdomen and pelvis
performed prior to FDG PET-CT examination.
CT protocol
CECT of the chest, abdomen and pelvis was most often
performed at our institution on a 64-section CT system (Sie-
mens Sensation; Siemens Healthcare, Erlangen, Germany)
(n =36) using a contiguous 5-mm reconstruction following a
bolus of 100 ml (75–125 ml) iodinated contrast medium. The
remaining CECT examinations were acquired on alternative
multidetector CT systems at our institution (n =3) or at one of
several regional referring hospitals (n =12) using similar scan
parameters.
FDG PET-CT protocol
FDG PET-CT examinations prior to June 2010 were
performed on a 16-section Discovery STE PET-CT system
(GE Healthcare, Amersham, UK), and from June 2010 on a
64-section Philips Gemini TF64 system (Philips Healthcare,
Best, The Netherlands). Total body FDG PET acquisition
from the skull vertex to the feet was acquired 60 min follow-
ing a 400-MBq dose of intravenous fluorine-18 FDG. The
low-dose unenhanced CT component was performed
according to a standardised protocol with the following set-
tings: 140 kV; 80mAs; tube rotation time 0.5 s per rotation;
pitch 6; section thickness 3.75 mm (to match the FDG PET
section thickness). Patients maintained normal shallow respi-
ration during the CT acquisition. Images were reconstructed
using a standard OSEM algorithm with CT for attenuation
correction. Both non-attenuation corrected and attenuation
corrected datasets were reconstructed.
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CECT imaging for each patient was retrieved from and
reviewed on the institutional picture archiving and communi-
cations system (PACS) (IMPAX™; AGFA Healthcare,
Mortsel, Belgium), whilst PET-CT imaging was reviewed on
a specialised PET-CT workstation (XD3; Mirada-Medical,
Oxford, UK). Comparison of prior CECT imaging with
PET-CT imaging was performed visually with no additional
co-registration software utilised. Imaging was retrospectively
reviewed by a consultant radiologist (experienced in PET-CT
reporting) and senior radiology registrar, both of whom are
members of the SSMDT. Clinical information and CECT
imaging were reviewed in conjunction with radiology reports
with standard size criteria used to determine lymph node
involvement and the presence of new, either solitary or mul-
tiple rounded pulmonary nodules of varying size, compatible
with pulmonary metastases. The availability of prior CECT
imaging overcame several limitations of low-dose unenhanc-
ed CT component of the PET-CT examination. Improved
anatomical detail allowed more definitive evaluation of lungs,
especially in the setting of indeterminate or potentially new
pulmonary findings, whilst contrast enhancement provided
conspicuity to lesions otherwise invisible on unenhanced
CT. Finally, the intervening period between the two examina-
tions provided a means to assess the rate of disease progres-
sion, which was of greatest benefit in the interpretation of
lesions with minimal FDG uptake. Visual interpretation of the
FDG PET-CT examination was qualitative with lesions with
FDG uptake above background mediastinal blood pool
classed as positive. Any discordances were discussed in order
to reach a consensus view.
Analysis of clinical impact
The relevant clinical and radiological information was analysed
using both our institutional patient pathway management sys-
tem (PPM™; Leeds Teaching Hospitals Trust, Leeds, UK) and
radiology information system (CRIS™; Healthcare Software
Systems, Banbury, UK) in conjunction with a consultant med-
ical oncologist who is also an integral member of the SSMDT.
The additional information provided by FDG PET-CT in com-
parison with prior CECT was used to assess its impact on
subsequent management decisions. A major clinical impact
was defined as a change in treatment plan, e.g. radical surgery
to systemic chemotherapy resulting from identification of ad-
ditional sites of disease or by characterisation of indeterminate
findings on prior CECT imaging. A minor impact was defined
as confirmation of known sites of disease as identified on prior
CECT. Potentially negative impacts due to false positive and
false negative results were also assessed. Confirmation of mul-
tifocal metastatic disease was achieved through follow-up im-
aging. In cases of potential oligometastatic disease on both CT
and PET-CT or in cases of discordance between the two imag-
ing modalities, histological confirmation was obtained through
percutaneous biopsy or surgical excision.
Results
Fifty-one FDG PET-CT examinations performed in 45 pa-
tients fulfilled the inclusion criteria for analysis. Six patients
underwent two FDG PET-CT examinations with a median
time interval of 8 months (range 3–12 months) between the
two studies; all patients had evidence of disease progression
on the second FDG PET-CT examination but none of the new
sites of disease identified were visible on review of the initial
FDG PET-CT examination. The study group included 28 men
and 17 women, with a median age of 60 years (range 29–
83 years). The original sites of the primary disease, American
Joint Committee on Cancer (AJCC) staging at the time of
FDG PET-CT and scan indications are listed in Table 1. The
median time interval between primary diagnosis and FDG
PET-CT examination was 52 months (range 3–217 months);
33 patients (73.3 %) experienced at least one or more previous
episodes of local or loco-regional recurrence in this interven-
ing period. The median time interval between CECT and
subsequent FDG PET-CT examination was 32 days (inter-
quartile range 20–56 days, range 6–107 days).
FDG PET-CT had a major impact on clinical management
in 21 cases (41.2 %), of which 18 examinations were per-
formed in patients with known or suspected AJCC stage IV
disease (Table 2). The majority of changes in clinical manage-
ment resulted from detection of additional sites of disease not
previously identified on CECT imaging often resulting in a
Table 1 Primary site of disease, AJCC staging and scan indication













Detection of additional sites of disease 35
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change from potentially radical surgery to systemic chemo-
therapy (Figs. 1 and 2). Frequently encountered sites of addi-
tional disease on FDG PET-CTwhich were ‘occult’ on CECT
imaging included subcutaneous and intra-muscular metastases
(n =8), sub-centimetre nodal disease (n =9), intra-abdominal
metastases including solid visceral (n =8), gastrointestinal
tract (n =2) and peritoneal deposits (n =3) and bone metasta-
ses (n =6).
In two cases of presumed oligometastatic stage IV MM,
FDG PET-CT identified additional sites of disease still amena-
ble to surgical management and resulted in a major impact by
altering and widening the field of surgical resection. A notable
case of major clinical impact occurred in a patient who, while
being assessed for a radical lymph node dissection, was diag-
nosed with stage IV MM on CECT imaging through the
identification of presumed multiple splenic metastases; FDG
PET-CT, however, successfully characterised these lesions as
benign via the absence of focal FDG activity within the spleen
and these remained stable on follow-up imaging over an 18-
month period (Fig. 3). In six cases, FDG PET-CT was used to
determine whether patients were eligible for entry into a che-
motherapeutic clinical trial for inoperable stage IVMM. In two
cases, a major impact resulted from the detection of FDG-avid
bone metastases that were not visible on CECT imaging,
resulting in exclusion from the trial.
FDG PET-CT had a minor impact in 23 cases (45.1 %)
where findings on prior CECT imaging were confirmed;
although no change in clinical management was effected,
confidence in the planned treatment was increased. There
were five false-positive cases (9.8 %) and two false-negative
Table 2 Details of cases in which 18F-FDG PET-CT had a major impact on clinical management
Stage Findings on CT Findings on 18F-FDG PET-CT Management alteration by PET-CT
III Suspicious cervical lymph nodes and
‘benign’
pulmonary nodule
Cervical nodal metastases and pulmonary metastasis Surgery Palliative
radiotherapy
III Solitary site of disease in the supraclavicular
fossa
Extensive locoregional soft tissue and nodal disease Surgery Chemotherapy
III Bilateral axillary masses Nodal, intramuscular, hepatic and bone metastases Surgery Chemotherapy
IV Suspicious pelvic and splenic lesions Necrotic pelvic lymph node. No focal FDG uptake
in the spleen
Chemotherapy Surgery
IV Pelvic abnormality No focal FDG uptake Surgery Routine follow-up
IV Solitary splenic metastasis Nodal, subcutaneous, solid visceral and small bowel
metastases
Surgery Chemotherapy
IV Axillary nodal disease and indeterminate
pancreatic mass
Axillary nodal disease and pancreatic metastasis Surgery Chemotherapy
IV Solitary adrenal metastasis and chronic
middle lobe atelectasis
Adrenal and middle lobe metastases Surgery Chemotherapy
IV Solitary hepatic metastasis 2 hepatic metastases not amenable to surgical
resection
Surgery Chemotherapy
IV Solitary hepatic metastasis 2 unilobar hepatic metastases Surgery Extended hepatic
surgery
IV Iliac pedicle lymph node metastasis Extensive locoregional nodal disease and femoral
bone metastasis
Surgery Chemotherapy
IV Lung and mesenteric nodal metastasis.
‘Hyperdense’ renal cysts
Pulmonary, nodal, gastric, gallbladder, renal
and peritoneal metastases
Surgery Chemotherapy
IV Suspicious locoregional nodes. Extensive locoregional nodal, subcutaneous
and intramuscular metastases
Chemotherapy Chemoradiotherapy
IV Subcutaneous, solid visceral and pulmonary
metastases










IV Suspicious iliac chain and retroperitoneal
lymph nodes
Extensive locoregional nodal disease Surgery Chemotherapy
IV Solitary hepatic metastasis Numerous hepatic and bone metastases Surgery Chemotherapy
IV Unilobar hepatic metastases Bilobar hepatic metastases Surgery Chemotherapy
IV Anterior abdominal wall and breast
metastases
Several additional soft tissue metastases Surgery Extended surgery
IV Unilobar hepatic metastases Widespread hepatic metastases and sacral bone
metastasis
Surgery Chemotherapy
IV Solitary chest wall metastasis Right axillary subcutaneous and supra-diaphragmatic
nodal disease
Surgery Chemotherapy
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cases (3.9 %) (Table 3). False-positive cases included two
instances in which FDG-avid lung nodules were incorrectly
labelled as metastatic melanoma deposits; in these cases diag-
noses of primary lung sarcoma and lung adenocarcinomawere
made following surgical resection. Although these lesions
were not melanoma metastases, they were malignant in
aetiology and PET-CT was beneficial in these cases through
the exclusion of distant metastatic disease prior to thoracic
surgery. Other false-positive cases included an endobronchial
FDG-avid focus histologically proven to be impacted inflam-
matory mucoid debris secondary to a proximal obstructing
FDG-avid endobronchial melanoma metastasis, FDG-avid
cervical lymphadenopathy with reactive histological changes
only and an FDG-avid soft-tissue lesion, compatible with
benign post-surgical change. False-negative cases included a
solitary 15-mm FDG-negative lung metastasis and an FDG-
negative sub-centimetre liver metastasis, incorrectly labelled
as benign, which on subsequent follow-up imaging had grown
in size in addition to the development of several new hepatic
metastases compatible with progressive disease.
Sub-group analysis of different time intervals between
FDG PET-CT and preceding CECT imaging revealed that 32
FDG PET-CTexaminations were performed less than 6 weeks
following CECTwith a major impact on clinical management
in 12 cases (37.5 %) and a minor impact in 13 cases (40.6 %).
Thirty-eight FDG PET-CT examinations were performed less
than 8 weeks following CECTwith major impact in 16 cases
(42.1 %) and minor impact in 15 cases (39.4 %). The numbers
of false-positive and false-negative cases were unchanged.
Discussion
This study shows that in patients with recurrent stage III/IV
MM, FDG PET-CT has a significant clinical impact when
compared with CECT of the chest, abdomen and the pelvis,
with an alteration in treatment strategy made in 21 cases
(41.2 %). Several studies have investigated the clinical impact
of FDG PET-CTonmanagement decisions, but there is a wide
range of figures (12–57.8 %) quoted in the literature [16, 18,
22–26]. This is due to varied study methodologies; in partic-
ular, the presence or absence of comparative baseline imaging
prior to FDG PET-CT examination and heterogeneous patient
cohorts undergoing FDG PET-CT examination, i.e. inclusion
of patients with all AJCC stages ofMMwith both primary and
recurrent disease, which makes it difficult to draw definitive
conclusions for the use of FDG PET-CT in specific patient
groups.
Our reported change in management of 41.2 % is at the
higher end of the quoted literature but there are several factors
underpinning this. Firstly, all FDG PET-CT examinations
were performed in patients with recurrent stage III/IV disease
and many of these patients had already experienced previous
episodes of local or loco-regional recurrence prior to FDG
PET-CT, which would be expected to increase the likelihood
of further disease recurrence. White et al. [1], in a study of
2,505 patients with stage III disease treated with radical lymph
node dissection, observed that most patients experienced some
form of recurrence within 2 years of surgery, with a 10-year
recurrence-free survival of only 20 %, and that distant disease
Fig. 1 A 37-year-old woman,
diagnosed with MM 8 years
previously and a prior right groin
recurrence 2 years later, was
found to have a solitary right 1.5-
cm iliac pedicle lymph node on a
surveillance CT. A subsequent
FDG PET-CT revealed several
sites of markedly FDG-avid
disease on the PET maximum
intensity projection (a) and
corresponding axial unenhanced
CT and fused PET-CT images
including the known enlarged
right iliac pedicle lymph node (b),
a 5-mm aorto-caval lymph node
(c), a 4-mm retroperitoneal
nodule overlying the right iliacus
muscle (d) and a solitary right
femoral bone metastasis
inconspicuous on CT (e). This
resulted in a change from
potential radical surgery to
chemotherapy—a major clinical
impact
Insights Imaging (2013) 4:701–709 705
predominated as the site of first recurrence in 44 % of patients.
Secondly, the majority of management decision alterations
were made in patients with oligometastatic stage IV disease,
indicating that haematogenous seeding of the tumour had
already occurred [2]. Both of these factors resulted in a high
pre-test probability that further sites of metastatic disease were
present. The number of treatment decision alterations made
through detection of additional sites of disease was therefore
likely to reflect a combination of this high pre-test probability
in addition to the improved detection of metastases, in partic-
ular subcutaneous and intra-muscular metastases, sub-
centimetre nodal disease, intra-abdominal metastases including
solid visceral, gastrointestinal tract and peritoneal deposits and
bone metastases, afforded by FDG PET-CT [10, 13].
The SSMDT at our tertiary institution is a double profes-
sorial unit (Dermatology and Clinical Oncology) and consists
of a number of other healthcare professionals, including der-
matologists, plastic surgeons, medical and clinical oncolo-
gists, radiologists, histopathologists and specialist nurses. It
provides direct access to highly specialist plastic surgery and
oncological services and the option for potential treatment
within clinical trials, all of which are only available in larger
centres. Every patient referred to the SSMDT has their pathol-
ogy and relevant imaging reviewed and, through open discus-
sion, a consensus decision is reached with regards to further
potential surgical, oncological and radiological management,
including referral for FDG PET-CT. A unique feature related
to our SSMDT is the availability of parallel clinic working,
whereby a joint clinic approach with dermatologists, medical
and clinical oncologists and plastic surgeons who are all in
attendance in one locality, enables expedient clinical discus-
sion and decision-making.
Examples where unique options available to our SSMDT
may have resulted in higher clinical impact include several
instances where surgery was being contemplated in patients
with more than one potential site of distant metastatic disease.
This reflects a more radical surgical approach adopted by a
tertiary centre SSMDT and the subsequent increased
utilisation of FDG PET-CT to optimise management in a
patient group that would not be routinely offered surgery.
Similarly, two cases of major clinical impact where FDG
PET-CT was used to determine eligibility for entry into a
Fig. 2 A 62-year-old man
diagnosed with MM 14 years
previously re-presented with a
biopsy proven left lower lobe
recurrence (a) and a suspicious
enlarged portocaval lymph node
(not shown) on a restaging CT.
Incidental findings of ‘gallstones’
and ‘hyperdense renal cysts’ were
also noted. A subsequent FDG
PET-CT revealed multiple sites of
markedly FDG-avid disease in the
chest, abdomen and pelvis
including an intramural gastric
cardia metastasis (b), an
intraluminal gallbladder
metastasis (‘gallstone’) (c) and a
3-mm left renal metastasis
(‘hyperdense renal cyst’) (d) as
seen on the axial PET images and
corresponding axial sections from
the prior CECT. This resulted in a
change from potential radical
surgery to chemotherapy—a
major clinical impact
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chemotherapeutic clinical trial, illustrate the unique options
available for treatment via a tertiary centre SSMDT and also
the fact that patients with inoperable late-stage MM undergo-
ing chemotherapy would not routinely undergo FDG PET-CT
examination.
The retrospective nature of this study and the relatively
small cohort coupled with an unequal proportion of examina-
tions performed in stage IV disease are potential limitations as
theymay positively skew the results and contribute to the high
estimation of the clinical impact of FDG PET-CT. Reporting
of the FDG PET-CTexamination with a lack of blinding to the
result of the prior CECT was likely to influence the positive
clinical impact of FDG PET-CT, but this methodology is
reflective of real life, day-to-day practice. In addition, it could
be argued that the median delay between CECT and subse-
quent FDG PET-CT examination of 32 days may have been
sufficient time for new sites of disease to develop in the
intervening period and become apparent on FDG PET-CT
and thereby falsely result in a major clinical impact by detec-
tion of additional sites of disease. However, sub-group
Fig. 3 A 67-year-old man with
previously treated lower limb
primary MM 7 months ago was
found to have suspicious pelvic
lymph nodes and multiple low
attenuation splenic lesions,
concerning for metastases on a
surveillance CT (a–c). A
subsequent FDG PET-CT
revealed a necrotic right pelvic
lymph node (not shown) and
normal appearances of the spleen,
as seen on the coronal PET image
(d). This resulted in a change
from potential chemotherapy to
radical surgery—a major clinical
impact
Table 3 Details of false-positive and false-negative cases
Case 18F-FDG PET-CT finding SUVmax Confirmed finding
False positives
1 FDG-avid cervical lymph nodes 4.6 Reactive lymphadenopathy only
2 FDG-avid soft-tissue lesion 2.8 Post-operative change
3 FDG-avid distal and (proximal) endobronchial lesions 18.1 (30.1) Distal lesion = impacted mucus(Proximal lesion = MM)
4 FDG-avid lung nodulea 23 Lung adenocarcinoma
5 FDG-avid lung nodulea 4.3 Lung sarcoma
False negatives
6 FDG-negative lung nodule N/A Lung metastasis
7 FDG-negative liver lesion N/A Progressive hepatic disease on follow-up imaging
a Cases in which PET-CT was of benefit in non-melanoma lesions
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analysis showed similar figures for change in management
with differing time intervals between FDGPET-CTand CECT
examinations.
A 41.2 % change in management represents a significant
clinical impact of FDG PET-CT in recurrent stage III/IV MM.
Despite similar results in the literature as detailed above and a
recent meta-analysis confirming FDG PET-CT as the superior
imaging modality for the detection of distant metastases in
both staging and surveillance of MM [14], even allowing for
its relative limitations in the detection of FDG-negative sub-
centimetre lung metastases [17] and brain metastases [18],
recommendations for its routine use are lacking in internation-
ally published guidelines [27–31].
The lack of recognition in international guidelines is likely
to reflect the absence of rigorous well-designed prospective
trials to address the clinical utility of FDG PET-CT in patients
with stage III/IV MM and, more importantly, its impact on
overall patient outcome and survival. In addition, with a
relatively expensive test, there are resultant cost implications
that need to be considered prior to wholesale endorsement of
this technique in guidelines.
Early studies have shown that FDG PETand FDG PET-CT
in the context of metastatic/recurrent melanoma or in the
specific context prior to pulmonary metastasectomy are cost-
effective options resulting in net savings [32, 33]. Most re-
cently, Bastiaannet et al. [34] performed a cost-effectiveness
study assessing the additional costs of adding FDG-PETor CT
to the diagnostic work-up of patients with stage III melanoma.
They reported that FDG PET and CECT was the most diag-
nostically accurate combination, upstaging a large proportion
of patients and thereby reducing the number of inappropriate
surgical procedures. However, reduced costs associated with
surgery and accompanying post-operative hospital stay were
negated by increased costs associatedwith a greater number of
patients receiving expensive systemic therapy options and the
cost associated with FDG PET itself. The additional cost of
PET and CT (with intravenous contrast) performed as sepa-
rate examinations to diagnostic pathway was 15.1 % as costs
for combined PET-CT were not yet established in The
Netherlands.
However, the addition of FDG PET only to the diagnostic
algorithm resulted in an additional cost of 7.2 %, which, in the
era of financial austerity, the authors felt was justifiable in
view of the benefits gained. One would expect that the addi-
tional costs of integrated PET-CT not to be too dissimilar to
FDG PET alone as most centres perform a low-dose
unenhanced CT, which avoids the additional costs associated
with intravenous contrast. In addition to a cost reduction, the
associated radiation exposure is significantly less and, impor-
tantly, the use of a low dose unenhanced CT does not signif-
icantly alter the diagnostic accuracy of integrated PET-CT for
lesion detection/characterisation or staging compared with a
contrast-enhanced CT component [35].
Conclusion
This study shows that FDG PET-CT has a significant clinical
impact on management decisions in patients with stage III/IV
MM through the detection of additional sites of distant meta-
static disease and characterisation of indeterminate findings
on CECT, which can alter or preclude potential surgical or
chemotherapeutic management. In addition, it provides a
unique insight into the experience of a highly specialised
tertiary centre SSMDT, through which individual cases are
discussed and patients are appropriately referred on for further
evaluation with FDG PET-CT. It also illustrates the more
radical surgical and chemotherapeutic options available via
the SSMDT, settings in which FDG PET-CT can be of bene-
ficial use. Prospective trials in stage-specific cohorts of pa-
tients in addition to further cost-effective analyses are required
to develop consensus opinion on the utilisation of FDG PET-
CT in MM.
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